Shares of Tilray Brands, Inc. (NASDAQ:TLRY – Get Free Report) have earned a consensus recommendation of “Hold” from the seven ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $20.00.
TLRY has been the subject of a number of research reports. Wall Street Zen upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Saturday, October 11th. Atb Cap Markets raised Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tilray Brands in a research note on Wednesday, October 8th.
View Our Latest Stock Report on TLRY
Institutional Trading of Tilray Brands
Tilray Brands Stock Down 5.4%
Shares of NASDAQ:TLRY opened at $9.60 on Friday. The firm has a market capitalization of $1.08 billion, a PE ratio of -0.42 and a beta of 1.76. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.56 and a current ratio of 2.62. Tilray Brands has a 52-week low of $3.51 and a 52-week high of $23.20. The firm has a fifty day moving average of $11.12 and a 200 day moving average of $10.25.
About Tilray Brands
Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.
Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.
Further Reading
- Five stocks we like better than Tilray Brands
- Do not delete, read immediately
- How the Rich Retire
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- How Long Will $1M Last in Retirement?
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Tilray Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Brands and related companies with MarketBeat.com's FREE daily email newsletter.
